BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 16862066)

  • 1. Metformin improves menstrual patterns, endocrine and metabolic profile in obese hyperinsulinemic women with a polycystic ovary syndrome.
    Krstevska B; Dimitrovski Ch; Pemovska G; Misevska S; Dimova Z; Simeonova S; Ahmeti I
    Prilozi; 2006 Jul; 27(1):57-66. PubMed ID: 16862066
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical, metabolic and endocrine parameters in response to metformin in obese women with polycystic ovary syndrome: a randomized, double-blind and placebo-controlled trial.
    Chou KH; von Eye Corleta H; Capp E; Spritzer PM
    Horm Metab Res; 2003 Feb; 35(2):86-91. PubMed ID: 12734787
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictive value of glucose-insulin ratio in PCOS and profile of women who will benefit from metformin therapy: obese, lean, hyper or normoinsulinemic?
    Onalan G; Goktolga U; Ceyhan T; Bagis T; Onalan R; Pabuçcu R
    Eur J Obstet Gynecol Reprod Biol; 2005 Dec; 123(2):204-11. PubMed ID: 16316811
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of long-term treatment with metformin added to hypocaloric diet on body composition, fat distribution, and androgen and insulin levels in abdominally obese women with and without the polycystic ovary syndrome.
    Pasquali R; Gambineri A; Biscotti D; Vicennati V; Gagliardi L; Colitta D; Fiorini S; Cognigni GE; Filicori M; Morselli-Labate AM
    J Clin Endocrinol Metab; 2000 Aug; 85(8):2767-74. PubMed ID: 10946879
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metformin therapy in women with polycystic ovary syndrome.
    Aruna J; Mittal S; Kumar S; Misra R; Dadhwal V; Vimala N
    Int J Gynaecol Obstet; 2004 Dec; 87(3):237-41. PubMed ID: 15548396
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The metabolic status modulates the effect of metformin on the antimullerian hormone-androgens-insulin interplay in obese women with polycystic ovary syndrome.
    Romualdi D; De Cicco S; Tagliaferri V; Proto C; Lanzone A; Guido M
    J Clin Endocrinol Metab; 2011 May; 96(5):E821-4. PubMed ID: 21307134
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increased endothelin-1 levels in women with polycystic ovary syndrome and the beneficial effect of metformin therapy.
    Diamanti-Kandarakis E; Spina G; Kouli C; Migdalis I
    J Clin Endocrinol Metab; 2001 Oct; 86(10):4666-73. PubMed ID: 11600523
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alteration of ghrelin-neuropeptide Y network in obese patients with polycystic ovary syndrome: role of hyperinsulinism.
    Romualdi D; De Marinis L; Campagna G; Proto C; Lanzone A; Guido M
    Clin Endocrinol (Oxf); 2008 Oct; 69(4):562-7. PubMed ID: 18248643
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effects of metformin on metabolic and cardiovascular risk factors in nonobese women with polycystic ovary syndrome.
    Sahin Y; Unluhizarci K; Yilmazsoy A; Yikilmaz A; Aygen E; Kelestimur F
    Clin Endocrinol (Oxf); 2007 Dec; 67(6):904-8. PubMed ID: 17666089
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of metformin therapy on hyperandrogenism in women with polycystic ovarian syndrome.
    Kazerooni T; Dehghan-Kooshkghazi M
    Gynecol Endocrinol; 2003 Feb; 17(1):51-6. PubMed ID: 12724019
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical and endocrinological effects of 6 months of metformin treatment in young hyperinsulinemic patients affected by polycystic ovary syndrome.
    Loverro G; Lorusso F; De Pergola G; Nicolardi V; Mei L; Selvaggi L
    Gynecol Endocrinol; 2002 Jun; 16(3):217-24. PubMed ID: 12192894
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Insulin sensitizing drugs increase the endogenous dopaminergic tone in obese insulin-resistant women with polycystic ovary syndrome.
    Ortega-González C; Cardoza L; Coutiño B; Hidalgo R; Arteaga-Troncoso G; Parra A
    J Endocrinol; 2005 Jan; 184(1):233-9. PubMed ID: 15642799
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Effects of metformin on the plasminogen activator system, endocrine, metabolic profiles in patients with polycystic ovary syndrome and clomiphene resistant cases].
    Song J; Shen H; Li J; Huang Z; Zhang Y
    Zhonghua Fu Chan Ke Za Zhi; 2002 Feb; 37(2):86-9. PubMed ID: 11953071
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metformin administration is more effective when non-obese patients with polycystic ovary syndrome show both hyperandrogenism and hyperinsulinemia.
    Genazzani AD; Lanzoni C; Ricchieri F; Baraldi E; Casarosa E; Jasonni VM
    Gynecol Endocrinol; 2007 Mar; 23(3):146-52. PubMed ID: 17454168
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effects of metformin on insulin resistance and ovarian steroidogenesis in women with polycystic ovary syndrome.
    Unlühizarci K; Keleştimur F; Bayram F; Sahin Y; Tutuş A
    Clin Endocrinol (Oxf); 1999 Aug; 51(2):231-6. PubMed ID: 10468995
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness of abdominal acupuncture for patients with obesity-type polycystic ovary syndrome: a randomized controlled trial.
    Zheng YH; Wang XH; Lai MH; Yao H; Liu H; Ma HX
    J Altern Complement Med; 2013 Sep; 19(9):740-5. PubMed ID: 23676106
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Endocrine and metabolic effects of metformin versus ethinyl estradiol-cyproterone acetate in obese women with polycystic ovary syndrome: a randomized study.
    Morin-Papunen LC; Vauhkonen I; Koivunen RM; Ruokonen A; Martikainen HK; Tapanainen JS
    J Clin Endocrinol Metab; 2000 Sep; 85(9):3161-8. PubMed ID: 10999803
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effects of rosiglitazone and metformin on insulin resistance and serum androgen levels in obese and lean patients with polycystic ovary syndrome.
    Yilmaz M; Biri A; Karakoç A; Törüner F; Bingöl B; Cakir N; Tiras B; Ayvaz G; Arslan M
    J Endocrinol Invest; 2005 Dec; 28(11):1003-8. PubMed ID: 16483179
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Effect of long-term treatment with metformin on steroid levels and parameters of insulin resistance in women with polycystic ovary syndrome].
    Vrbíková J; Hill M; Stárka L; Cibula D; Snajderová M; Sulcová J; Vondra K; Bendlová B
    Cas Lek Cesk; 2001 Nov; 140(22):688-94. PubMed ID: 11789058
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of metformin and ethinyl estradiol-cyproterone acetate on clinical, endocrine and metabolic factors in women with polycystic ovary syndrome.
    Wu J; Zhu Y; Jiang Y; Cao Y
    Gynecol Endocrinol; 2008 Jul; 24(7):392-8. PubMed ID: 18608522
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.